AI Reshapes Drug Discovery

Artificial intelligence is moving deeper into pharmaceutical research, changing how companies identify drug targets, design molecules and decide which experiments to run. The opportunity extends beyond speeding up laboratory work: AI could help pharmaceutical companies reduce costly research bottlenecks and improve the odds of developing medicines that succeed in clinical trials.

A new industry analysis highlighted by Bernstein points to a growing need for experimental data as pharmaceutical companies expand their use of AI. Demand is no longer concentrated among small biotechnology start-ups; major drugmakers are increasingly investing in the data and laboratory infrastructure needed to train, test and validate AI systems.

For investors, this creates a potential opportunity across the pharmaceutical technology supply chain—from advanced imaging and genetic sequencing to laboratory automation and specialist software.

AI Needs Real-World Experiments

chem-space.com

AI models can predict how molecules might behave, identify promising compounds and help researchers narrow the number of experiments required. But predictions still need to be tested in physical laboratory settings.

That requirement is creating a growing market for high-value experimental data. According to findings discussed by Bernstein, demand for certain datasets has increased tenfold or even 100-fold in some cases as pharmaceutical companies scale up their AI research programmes.

This creates a feedback loop: AI proposes promising candidates, laboratory experiments test those predictions, and the resulting data can be used to improve future models. The more effectively companies connect these stages, the greater the potential to reduce wasted experiments and accelerate research.

Laboratory Technology Could Benefit

The growth of AI-driven research may create opportunities for companies supplying the equipment and technologies needed to generate complex biological data.

Several publicly traded businesses are positioned in this ecosystem:

Revvity (NYSE: RVTY): Provides laboratory instruments and high-content imaging systems used to study cellular responses. Bernstein highlighted its Opera Phenix platform as a potential beneficiary of increasing demand.
10x Genomics (NASDAQ: TXG): Supplies technologies that help researchers analyse biological systems at cellular resolution.
Illumina (NASDAQ: ILMN): Provides sequencing systems that can generate large volumes of genomic data for research and drug development.

These companies do not all benefit in the same way. Higher testing volumes can increase demand for instruments, consumables and sequencing services, but falling prices per data point may limit revenue growth. Competition, capital spending and the financial health of biotechnology customers also influence results.

AI Could Change Clinical Trials

The longer-term opportunity extends beyond preclinical research. AI systems are increasingly being used to simulate how different patient populations might respond to experimental medicines before companies commit to expensive human trials.

The pharmaceutical industry spends approximately $140 billion annually on human clinical testing, yet only around 12% of drug candidates ultimately receive regulatory approval, according to figures cited by Reuters. AI simulations could help researchers identify weak candidates earlier and direct resources towards programmes with stronger prospects.

These systems are not substitutes for clinical evidence. Simulations can miss important biological factors, rely on incomplete historical data or produce incorrect predictions. Human trials remain essential for establishing whether a treatment is safe and effective.

The potential benefit is therefore not simply to run trials faster, but to make better decisions about which trials should proceed.

The Investment Opportunity Has Risks

The commercial impact of AI-driven drug discovery will depend on whether improved research tools translate into better development outcomes.

For laboratory suppliers, rising demand could support instrument sales, consumables and recurring service revenue. However, customers may delay equipment purchases if biotechnology funding weakens, and increased data volumes do not necessarily translate into higher margins.

For pharmaceutical companies, the potential rewards are larger but less predictable. Identifying a promising molecule more quickly does not guarantee that it will succeed in human trials, secure regulatory approval or generate commercial returns.

McKinsey’s September 2026 analysis also cautioned that many AI-enabled drug programmes remain in early clinical development. While selected programmes have reached milestones faster than traditional benchmarks, the technology’s overall impact on late-stage clinical success remains unproven.

What Investors Should Watch

The next phase of AI adoption in pharmaceutical research will be shaped by three factors:

Evidence of improved outcomes: Whether AI meaningfully increases clinical success rates, rather than simply generating more drug candidates.
Laboratory spending: Whether pharmaceutical companies continue investing in advanced imaging, sequencing, automation and experimental data.
Commercial returns: Whether suppliers can convert higher demand into sustainable revenue and profits despite pricing pressure.

The companies best positioned may be those providing indispensable experimental capabilities that AI cannot replace. Generating reliable biological evidence remains essential even as models become more sophisticated.

AI’s Pharma Revolution Is Still Developing

AI is reshaping pharmaceutical research by changing how scientists identify targets, design molecules and select experiments. Its adoption is also creating opportunities for laboratory equipment and data-generation businesses as drugmakers expand their research capabilities.

The strongest long-term outcome would be a measurable improvement in the probability that experimental medicines become safe, effective treatments. That could reduce wasted development spending and help pharmaceutical companies allocate capital more efficiently.

For investors, the opportunity is real but still developing. Growing demand for AI-related research infrastructure is an important signal, while clinical validation and sustained commercial returns will ultimately determine which businesses emerge as long-term winners.